arrow_back Back Filing freshness 10-K FY 2026 SEC EDGAR

NEOGEN CORP

NEOG
$11.46 ▲ +0.16 (+1.46%) at close
Healthcare ·In Vitro & In Vivo Diagnostic Substances ·USIn Vitro & In Vivo Diagnostic Substances
18 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
36
Health
Weak
Bearish
auto_awesome

Analytical Summary

NEOGEN CORP faces fundamental challenges with weakness in Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $2.5B
Dividend Yield
Revenue Growth -2.7%
Op. Margin -2.5%
ROIC -0.7%
FCF / Share $0.38
Trailing P/E
Price / Book 1.2x
FCF Yield 3.3%
Debt / Equity 0.38
info Valuation on last close. End-of-day price, Aug 7, 2026.

18-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$870.40M
↓ -2.7%
Net Income Profit after all expenses
$-7.90M
↑ +99.3%
Operating Margin Operating profit as % of sales
-2.5%
↑ +97.9% 24th
FCF / Share Free cash flow per share
$0.38
↑ +42.6%
Long-Term Debt Long-term obligations
$793.70M
↓ -9.3%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile

Health Breakdown

Profitability
36
Returns
40
Financial Health
48
Cash Quality
3

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 18 years · 66 quarters